Email Facebook Twitter

ShareCast News - Broker Recommendations

Broker tips: AB Foods, ARM, Wolseley...

Panmure Gordon has upgraded its rating for Associated British Foods from 'hold' to 'buy' after the company announced its intention to expand its fast-growing Primark brand into the US towards the end of next year.
[Yesterday 12:59]

Spirent's Q1 figures 'not as good as they appear', says Investec

Spirent Communications's first-quarter results impressed the market on Wednesday with revenues and profits ahead of expectations, though Investec said that figures are 'not as good as they appear on the surface'.
[Yesterday 12:29]

Citi upgrades AstraZeneca on under-appreciated pipeline

The potential value of AstraZeneca's (AZN) drug pipeline is still under-appreciated by the market, with or without a bid from US pharmaceutical peer Pfizer (PFE), according to Citigroup.
[Yesterday 11:08]

Credit Suisse sees substantial capital returns at Wolseley

Wolseley's share price was making gains on Wednesday after Credit Suisse upgraded the stock from 'neutral' to 'outperform', saying that it foresees substantial capital returns at the plumbing and building materials group.
[Yesterday 10:29]

ARM needs stronger growth to justify valuation, says finnCap

finnCap has reiterated its 'hold' rating and 1,000p target price for chip designer ARM Holdings after the company's first-quarter results showed strong licensing revenues and weak royalties.
[Yesterday 10:09]

Panmure upgrades AB Foods on Primark expansion into US

Panmure Gordon has upgraded its rating for Associated British Foods from 'hold' to 'buy' after the company announced its intention to expand its fast-growing Primark brand into the US.
[Yesterday 10:00]

Wednesday broker round-up UPDATE

AstraZeneca: Citi raises target price from 3500p to 4900p and upgrades to buy.
[Yesterday 09:04]

Jefferies foresees 'robust' earnings growth at Shire

Jefferies has raised its target price for pharmaceuticals group Shire, saying that the recent share-price weakness has presented an 'attractive buying opportunity'.
[Tue 13:01]

Broker tips: AstraZeneca, GlaxoSmithKline, Shire, Pets at Home

Societe Generale has kept a 'sell' recommendation on AstraZeneca (AZN), questioning the reasoning behind a potential takeover by US pharmaceutical peer Pfizer.
[Tue 12:53]

Killik hails major Glaxo deal with Novartis

Killik has maintained a 'buy' recommendation on GlaxoSmithKline (GSK), saying that the company's major three-part transaction with Swiss pharmaceuticals peer Novartis on Tuesday will accelerate growth, provide cost savings and generate increased returns.
[Tue 12:27]

Categories: AIM Bulletin, Broker Recommendations, Commodities, Company News, Dealings and Holdings, Economic News, Foreign Exchange, International News, Market Report, New Issues, News and Announcements, Press Round-Up, Risers and Fallers, Small Cap News, Technical Analysis, Tips Round-Up, Week Ahead.

Sign up for Live Prices

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.